Developer docs
API playgroundTry for free, no card

Search company profiles

Aprea Therapeutics

Full company profile

uuid02meubk

Namestring
Aprea Therapeutics
Legal namestring
Aprea Therapeutics, Inc.
Websiteurl
aprea.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target the DNA Damage Response (DDR) pathway in cancer, with particular emphasis on restoring function of the tumor suppressor p53. Founded in Sweden in 2003, the company is headquartered in Doylestown, Pennsylvania with research and development operations in Stockholm, Sweden, and became a U.S. public company following its incorporation in Delaware in May 2019 and its October 2019 listing on NASDAQ under the ticker APRE, which raised approximately $97.75 million.

The company's pipeline is anchored by eprenetapopt (APR-246), an intravenously administered small molecule that reactivates mutant p53, supplemented by APR-548 (an oral p53 reactivator), APR-1051 (a WEE1 inhibitor), and ATR/ATRi programs acquired through the 2022 acquisition of Atrin Pharmaceuticals. Eprenetapopt has been granted FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations for myelodysplastic syndromes (MDS), where Phase 3 enrollment of 154 patients was completed in June 2020. Reported net losses were $6.2 million in Q3 2019 and $9.4 million in Q1 2020, with cash and equivalents of $122.5 million as of March 31, 2020.

Aprea is pre-revenue and does not currently sell any approved products. Its business model is contingent on successful clinical advancement of its candidates toward regulatory approval, at which point revenue would be generated either through direct commercialization (targeting oncologists, academic cancer centers, and hospital systems treating TP53-mutant MDS, AML, and solid tumor patients) or through partnership, out-licensing, or strategic transactions. As a result, current cash flow is purely a function of capital raised (equity offerings) netted against R&D and G&A burn, with no product-derived revenue line.

Short descriptiontext

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule DNA Damage Response (DDR) targeted cancer therapeutics, most notably p53 reactivator eprenetapopt for TP53-mutant MDS, with additional WEE1 and ATR inhibitor programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDoylestown, United States
HQ citystring
Doylestown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DDR targeted therapeutics, p53 reactivator oncology, precision medicine cancer, small molecule inhibitors, biopharmaceutical drug development
Industry1 code
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-commercial biopharmaceutical company focused on developing novel cancer therapeutics. Revenue will be generated through commercialization of approved drug products, primarily in the oncology/hematology space. Currently in clinical trial stage with no commercialized products generating revenue.

ir.aprea.com
2Future Product Sales
TypeOne Time License
Description

Revenue anticipated from sales of approved DDR-targeted cancer therapeutics, including APR-246 (eprenetapopt) and other pipeline candidates upon successful clinical development and regulatory approval.

aprea.com
3Regulatory Exclusivity and IP Licensing
TypeLicensing Royalties
Description

Company holds Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA providing potential regulatory exclusivity benefits. May pursue licensing agreements for pipeline assets.

ir.aprea.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing DNA Damage Response (DDR)-targeted small molecule cancer therapeutics using a precision medicine approach. Its lead product candidate APR-246 (eprenetapopt) is a first-in-class p53 reactivator in Phase 3 development in combination with azacitidine for TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The pipeline also includes the next-generation oral p53 reactivator APR-548, the WEE1 inhibitor APR-1051, and an ATR inhibitor program acquired via Atrin Pharmaceuticals in 2022.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 MDS trial fully enrolled with 154 patients with primary endpoint of complete remission (CR) rate
+2 more records
Product overview1 text field

Aprea Therapeutics is a biopharmaceutical company developing DDR (DNA Damage Response)-targeted small molecule cancer therapeutics using a precision medicine approach. The company's product portfolio centers on p53 tumor suppressor protein reactivation, with lead product candidate APR-246 (eprenetapopt), a small molecule in clinical development for hematologic malignancies including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Additional pipeline candidates include APR-548 (next-generation oral p53 reactivator) and APR-1051 (WEE1 inhibitor). The company develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Groupe Francophone des Myélodysplasies (GFM)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

French clinical research cooperative group conducting investigator-initiated Phase 2 trial of APR-246 with azacitidine in TP53 mutated MDS and AML patients. This collaboration provides access to French clinical sites and expertise in myelodysplastic syndromes.

ir.aprea.com
2U.S. Clinical Trial Sites
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple U.S. medical centers and oncology practices participating in Phase 1b/2 investigator-initiated trial of APR-246 with azacitidine for frontline treatment of TP53 mutant MDS and AML patients.

ir.aprea.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biopharma developing azenosertib, a WEE1 inhibitor in co-development with Pfizer, GSK and Zentera. Directly comparable to Aprea's APR-1051 WEE1 program and shares the DDR pathway focus in hematologic malignancies.

TypeDirect peer
Description

Clinical-stage oncology company developing synthetic-lethality and DDR-targeted therapies, including PRMT5 and USP1 inhibitors. Comparable as a small-cap, DDR-focused oncology biotech with multiple clinical assets.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic-lethality and DDR-targeted therapies including ATR inhibitors and polymerase theta inhibitors. Directly comparable to Aprea on DDR mechanism and small-cap clinical-stage oncology profile.

4Theseus Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharma developing DDR kinase inhibitors (including a next-generation KIT inhibitor) for cancer. Comparable as a small-cap clinical-stage oncology company targeting DDR biology.

TypeEmerging player
Description

Clinical-stage precision oncology company developing allosteric mutation-targeted therapies across multiple oncogenic drivers. Comparable to Aprea in being a small-cap, mutation-targeted oncology company with a discovery-to-clinical pipeline.

TypeEmerging player
Description

Computational drug discovery company with a clinical-stage oncology pipeline developed through its platform. Comparable as a smaller-cap, technology-enabled oncology drug developer, though with a different core approach.

TypeBroad incumbent
Description

Global pharmaceutical company with an extensive DDR and oncology pipeline, including a co-development deal with Zentalis on the WEE1 inhibitor azenosertib. Comparable as a broad incumbent with overlapping DDR/oncology programs and potential acquirer of Aprea.

TypeBroad incumbent
Description

Global pharmaceutical company with a large oncology franchise and active DDR/synthetic-lethality programs (e.g., MDM2, CDK4/6). Comparable as a broad incumbent with overlapping oncology DDR strategy and as a potential strategic acquirer of Aprea.

TypeBroad incumbent
Description

Global pharmaceutical company with Keytruda as a backbone for combination oncology strategies (relevant to APR-246 + anti-PD-1 trials). Comparable as a broad incumbent with significant DDR and immuno-oncology combination strategy that intersects with Aprea's pipeline.

TypeBroad incumbent
Description

Global pharmaceutical company with an active DDR and synthetic-lethality oncology pipeline (e.g., PARP, ATM, WEE1 programs via partnerships). Comparable as a broad incumbent in DDR oncology and a potential strategic acquirer of DDR-focused biotechs like Aprea.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aprea Therapeutics

Oncology Therapeuticsaprea.com

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule DNA Damage Response (DDR) targeted cancer therapeutics, most notably p53 reactivator eprenetapopt for TP53-mutant MDS, with additional WEE1 and ATR inhibitor programs.

What Aprea Therapeutics does

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target the DNA Damage Response (DDR) pathway in cancer, with particular emphasis on restoring function of the tumor suppressor p53. Founded in Sweden in 2003, the company is headquartered in Doylestown, Pennsylvania with research and development operations in Stockholm, Sweden, and became a U.S. public company following its incorporation in Delaware in May 2019 and its October 2019 listing on NASDAQ under the ticker APRE, which raised approximately $97.75 million.

The company's pipeline is anchored by eprenetapopt (APR-246), an intravenously administered small molecule that reactivates mutant p53, supplemented by APR-548 (an oral p53 reactivator), APR-1051 (a WEE1 inhibitor), and ATR/ATRi programs acquired through the 2022 acquisition of Atrin Pharmaceuticals. Eprenetapopt has been granted FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations for myelodysplastic syndromes (MDS), where Phase 3 enrollment of 154 patients was completed in June 2020. Reported net losses were $6.2 million in Q3 2019 and $9.4 million in Q1 2020, with cash and equivalents of $122.5 million as of March 31, 2020.

Aprea is pre-revenue and does not currently sell any approved products. Its business model is contingent on successful clinical advancement of its candidates toward regulatory approval, at which point revenue would be generated either through direct commercialization (targeting oncologists, academic cancer centers, and hospital systems treating TP53-mutant MDS, AML, and solid tumor patients) or through partnership, out-licensing, or strategic transactions. As a result, current cash flow is purely a function of capital raised (equity offerings) netted against R&D and G&A burn, with no product-derived revenue line.

Aprea Therapeutics firmographics

Firmographics
Name
Aprea Therapeutics
Legal name
Aprea Therapeutics, Inc.
Website
https://aprea.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule DNA Damage Response (DDR) targeted cancer therapeutics, most notably p53 reactivator eprenetapopt for TP53-mutant MDS, with additional WEE1 and ATR inhibitor programs.
Ownership category
akta.pro rank

Aprea Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • DDR targeted therapeutics
  • P53 reactivator oncology
  • Precision medicine cancer
  • Small molecule inhibitors
  • Biopharmaceutical drug development

Where Aprea Therapeutics is headquartered

Location

Headquarters

HQ city
Doylestown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aprea Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-commercial biopharmaceutical company focused on developing novel cancer therapeutics. Revenue will be generated through commercialization of approved drug products, primarily in the oncology/hematology space. Currently in clinical trial stage with no commercialized products generating revenue.
  2. Future Product Sales: Revenue anticipated from sales of approved DDR-targeted cancer therapeutics, including APR-246 (eprenetapopt) and other pipeline candidates upon successful clinical development and regulatory approval.
  3. Regulatory Exclusivity and IP Licensing: Company holds Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA providing potential regulatory exclusivity benefits. May pursue licensing agreements for pipeline assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aprea Therapeutics product offering

Product offering

Core offering

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing DNA Damage Response (DDR)-targeted small molecule cancer therapeutics using a precision medicine approach. Its lead product candidate APR-246 (eprenetapopt) is a first-in-class p53 reactivator in Phase 3 development in combination with azacitidine for TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The pipeline also includes the next-generation oral p53 reactivator APR-548, the WEE1 inhibitor APR-1051, and an ATR inhibitor program acquired via Atrin Pharmaceuticals in 2022.

Product overview

Aprea Therapeutics is a biopharmaceutical company developing DDR (DNA Damage Response)-targeted small molecule cancer therapeutics using a precision medicine approach. The company's product portfolio centers on p53 tumor suppressor protein reactivation, with lead product candidate APR-246 (eprenetapopt), a small molecule in clinical development for hematologic malignancies including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Additional pipeline candidates include APR-548 (next-generation oral p53 reactivator) and APR-1051 (WEE1 inhibitor). The company develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Phase 3 MDS trial fully enrolled with 154 patients with primary endpoint of complete remission (CR) rate
  • +2 more outcomes

Companies that use Aprea Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Aprea Therapeutics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aprea Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Groupe Francophone des Myélodysplasies (GFM)coreStrategic or Co-development PartnerFrench clinical research cooperative group conducting investigator-initiated Phase 2 trial of APR-246 with azacitidine in TP53 mutated MDS and AML patients. This collaboration provides access to French clinical sites and expertise in myelodysplastic syndromes.
  • U.S. Clinical Trial SitescoreStrategic or Co-development PartnerMultiple U.S. medical centers and oncology practices participating in Phase 1b/2 investigator-initiated trial of APR-246 with azacitidine for frontline treatment of TP53 mutant MDS and AML patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Aprea Therapeutics competitors and assessment

Company assessment

Direct peers

  • Zentalis Pharmaceuticals: Clinical-stage oncology biopharma developing azenosertib, a WEE1 inhibitor in co-development with Pfizer, GSK and Zentera. Directly comparable to Aprea's APR-1051 WEE1 program and shares the DDR pathway focus in hematologic malignancies.
  • Tango Therapeutics: Clinical-stage oncology company developing synthetic-lethality and DDR-targeted therapies, including PRMT5 and USP1 inhibitors. Comparable as a small-cap, DDR-focused oncology biotech with multiple clinical assets.
  • Repare Therapeutics: Clinical-stage precision oncology company developing synthetic-lethality and DDR-targeted therapies including ATR inhibitors and polymerase theta inhibitors. Directly comparable to Aprea on DDR mechanism and small-cap clinical-stage oncology profile.
  • Theseus Pharmaceuticals: Clinical-stage biopharma developing DDR kinase inhibitors (including a next-generation KIT inhibitor) for cancer. Comparable as a small-cap clinical-stage oncology company targeting DDR biology.

Emerging players

  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric mutation-targeted therapies across multiple oncogenic drivers. Comparable to Aprea in being a small-cap, mutation-targeted oncology company with a discovery-to-clinical pipeline.
  • Schrödinger: Computational drug discovery company with a clinical-stage oncology pipeline developed through its platform. Comparable as a smaller-cap, technology-enabled oncology drug developer, though with a different core approach.

Broad incumbents

  • Pfizer: Global pharmaceutical company with an extensive DDR and oncology pipeline, including a co-development deal with Zentalis on the WEE1 inhibitor azenosertib. Comparable as a broad incumbent with overlapping DDR/oncology programs and potential acquirer of Aprea.
  • Novartis: Global pharmaceutical company with a large oncology franchise and active DDR/synthetic-lethality programs (e.g., MDM2, CDK4/6). Comparable as a broad incumbent with overlapping oncology DDR strategy and as a potential strategic acquirer of Aprea.
  • Merck & Co. Global pharmaceutical company with Keytruda as a backbone for combination oncology strategies (relevant to APR-246 + anti-PD-1 trials). Comparable as a broad incumbent with significant DDR and immuno-oncology combination strategy that intersects with Aprea's pipeline.
  • AstraZeneca: Global pharmaceutical company with an active DDR and synthetic-lethality oncology pipeline (e.g., PARP, ATM, WEE1 programs via partnerships). Comparable as a broad incumbent in DDR oncology and a potential strategic acquirer of DDR-focused biotechs like Aprea.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Aprea Therapeutics social profiles

Digital presence

Aprea Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aprea Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Aprea Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Aprea Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aprea Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aprea Therapeutics

What does Aprea Therapeutics do?

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing DNA Damage Response (DDR)-targeted small molecule cancer therapeutics using a precision medicine approach. Its lead product candidate APR-246 (eprenetapopt) is a first-in-class p53 reactivator in Phase 3 development in combination with azacitidine for TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The pipeline also includes the next-generation oral p53 reactivator APR-548, the WEE1 inhibitor APR-1051, and an ATR inhibitor program acquired via Atrin Pharmaceuticals in 2022.

Is Aprea Therapeutics a public or private company?

Aprea Therapeutics is a public company. It is classified as public and is currently operating.

When was Aprea Therapeutics founded?

Aprea Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is Aprea Therapeutics based?

Aprea Therapeutics is headquartered in Doylestown, United States, in the North America region.

How does Aprea Therapeutics make money?

Three revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are future Product Sales and regulatory Exclusivity and IP Licensing.

Who are Aprea Therapeutics's main competitors?

Direct peers on record are Zentalis Pharmaceuticals, Tango Therapeutics, Repare Therapeutics and Theseus Pharmaceuticals. Emerging players are Black Diamond Therapeutics and Schrödinger. Broad incumbents are Pfizer, Novartis, Merck & Co. and AstraZeneca.

Does Aprea Therapeutics have an API?

No public API is recorded for Aprea Therapeutics.

What industry is Aprea Therapeutics in?

Aprea Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAprea Therapeutics To Present At The Guggenheim 3Rd Annual Healthcare Innovation ConferenceAprea Therapeutics will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The company's technology targets cancer cell mutations to minimize toxicity, with lead programs APR-1051 and ATRN-119 in clinical development for solid tumors.MarketScreenerAprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Aprea Therapeutics reported a Q3 net loss of $4.81 million and a nine-month net loss of $11.69 million, both down from prior-year figures. Basic and diluted loss per share from continuing operations were $0.09 and $0.29, respectively, compared to $0.47 and $1.65 a year ago. The company's pipeline includes two clinical-stage synthetic lethality programs, APR-1051 and ATRN-119.BarchartWheat Falls on Wednesday with Black Sea NewsAprea Therapeutics is developing APR-1051, a next-generation WEE1 inhibitor, aiming to improve safety and tolerability over earlier drugs. The company estimates a $3-5 billion market for standalone WEE1 inhibitors, with potential expansion via combination therapies. Upcoming clinical results will determine whether APR-1051 can compete with Zentalis.Investing.comAprea at Pre-ESMO Virtual Panel Conference: wEE1 bet leans on safetyAprea Therapeutics presented its Pre-ESMO virtual panel on WEE1 inhibition, highlighting APR-1051 as a next-generation inhibitor with improved safety. The company estimated a near-term U.S. market of about 20,000 patients, translating to $3–5 billion in monotherapy sales potential. Aprea plans an interim ACESOT-1051 update at ESMO in about a month.American Banking and Market NewsContrasting Aprea Therapeutics (NASDAQ:APRE) & CRISPR Therapeutics (NASDAQ:CRSP)Aprea Therapeutics and CRISPR Therapeutics are compared on financial metrics, analyst ratings, and ownership. CRISPR beats Aprea on 9 of 15 factors, but analysts see higher upside in Aprea. CRISPR is more affordable on valuation, while Aprea has higher earnings.Ticker ReportAlkermes (NASDAQ:ALKS) & Aprea Therapeutics (NASDAQ:APRE) Financial AnalysisAlkermes and Aprea Therapeutics are compared on financial metrics, with Alkermes showing higher revenue and earnings but lower analyst upside. Aprea's stock has a higher potential upside of 304.57% versus Alkermes' 16.72%, and Alkermes beats Aprea on 11 of 15 factors.BioSpaceAprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceAprea Therapeutics CEO Oren Gilad will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, with a webcast on September 14. The company's lead programs are APR-1051 and ATRN-119, both in clinical development for solid tumors.BioSpaceAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsAprea Therapeutics announced an expansion of its intellectual property portfolio for precision oncology programs, with 28 issued and 30 pending patents. The WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119 are covered, with patents expiring into 2045. The company is considering further ATRN-119 development in combination approaches.BioWorldASCO 2026: Drugmakers go ‘WEE1’ for early dataAt ASCO 2026, Aprea Therapeutics presented phase 1 data for its WEE1 inhibitor APR-1051, showing two partial responses in endometrial cancer patients. Zentalis Pharmaceuticals reported a phase Ib study of azenosertib plus paclitaxel in platinum-resistant ovarian cancer, achieving a 39% overall response rate and median progression-free survival of 7.3 months.GlobeNewswireAprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesAprea Therapeutics set the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in the ABOYA-119 study. The company paused further monotherapy enrollment to focus on combination therapies, including with radiation and checkpoint inhibitors. It plans to present updated data at the AACR conference.